GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Genetic Signatures Ltd (ASX:GSS) » Definitions » Cash Ratio

Genetic Signatures (ASX:GSS) Cash Ratio : 4.73 (As of Dec. 2023)


View and export this data going back to 2015. Start your Free Trial

What is Genetic Signatures Cash Ratio?

The Cash Ratio measures a company’s ability to meet its short-term obligations with cash and near-cash resources. It is calculated as a company's Cash, Cash Equivalents, Marketable Securities divides by its Total Current Liabilities. Genetic Signatures's Cash Ratio for the quarter that ended in Dec. 2023 was 4.73.

Genetic Signatures has a Cash Ratio of 4.73. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.

The historical rank and industry rank for Genetic Signatures's Cash Ratio or its related term are showing as below:

ASX:GSS' s Cash Ratio Range Over the Past 10 Years
Min: 2.01   Med: 6.96   Max: 23.11
Current: 4.73

During the past 9 years, Genetic Signatures's highest Cash Ratio was 23.11. The lowest was 2.01. And the median was 6.96.

ASX:GSS's Cash Ratio is ranked better than
89.18% of 231 companies
in the Medical Diagnostics & Research industry
Industry Median: 1.06 vs ASX:GSS: 4.73

Genetic Signatures Cash Ratio Historical Data

The historical data trend for Genetic Signatures's Cash Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genetic Signatures Cash Ratio Chart

Genetic Signatures Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Cash Ratio
Get a 7-Day Free Trial Premium Member Only 4.09 9.34 6.51 7.68 2.69

Genetic Signatures Semi-Annual Data
Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Cash Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 9.63 7.68 6.09 2.69 4.73

Competitive Comparison of Genetic Signatures's Cash Ratio

For the Diagnostics & Research subindustry, Genetic Signatures's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Genetic Signatures's Cash Ratio Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Genetic Signatures's Cash Ratio distribution charts can be found below:

* The bar in red indicates where Genetic Signatures's Cash Ratio falls into.



Genetic Signatures Cash Ratio Calculation

The Cash Ratio measures a company's ability to meet its short-term obligations with its cash and near-cash resources.

Genetic Signatures's Cash Ratio for the fiscal year that ended in Jun. 2023 is calculated as:

Cash Ratio (A: Jun. 2023 )=Cash, Cash Equivalents, Marketable Securities/Total Current Liabilities
=16.349/6.069
=2.69

Genetic Signatures's Cash Ratio for the quarter that ended in Dec. 2023 is calculated as:

Cash Ratio (Q: Dec. 2023 )=Cash, Cash Equivalents, Marketable Securities/Total Current Liabilities
=18.124/3.83
=4.73

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Genetic Signatures  (ASX:GSS) Cash Ratio Explanation

The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.

The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.

In general, the higher the cash ratio, the better the company's liquidity position.


Genetic Signatures Cash Ratio Related Terms

Thank you for viewing the detailed overview of Genetic Signatures's Cash Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Genetic Signatures (ASX:GSS) Business Description

Traded in Other Exchanges
N/A
Address
7 Eliza Street, Newtown, Sydney, NSW, AUS, 2042
Genetic Signatures Ltd proprietary PCR solutions and automated workflows routinely screen for multiple infectious diseases in a single test. Rapid and accurate results facilitate improved patient management and healthcare outcomes. GSS continues to expand its global reach with direct representation in Australia, Europe, and the United States, and growing distribution partnerships. The company operates under one business segment which is the research and commercialisation of identifying individual genetic signatures to diagnose diseases and disabilities.